LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 118

Search options

  1. Article ; Online: Possible immunoglobulin-E-dependent sugammadex-induced anaphylaxis caused by an epitope other than γ-cyclodextrin: a case report.

    Horiuchi, Tatsuo / Takazawa, Tomonori / Sakamoto, Shinya / Orihara, Masaki / Yokohama, Akihiko / Uchiyama, Mutsumi / Saito, Shigeru

    Journal of medical case reports

    2021  Volume 15, Issue 1, Page(s) 313

    Abstract: Background: Sugammadex is a synthetic γ-cyclodextrin derivative designed to selectively bind to steroidal neuromuscular blocking agents and reverse their effects. Although many cases of sugammadex-induced anaphylaxis have been reported, few studies have ...

    Abstract Background: Sugammadex is a synthetic γ-cyclodextrin derivative designed to selectively bind to steroidal neuromuscular blocking agents and reverse their effects. Although many cases of sugammadex-induced anaphylaxis have been reported, few studies have investigated the underlying mechanism.
    Case presentation: A 55-year-old Japanese man underwent a laryngectomy under general anesthesia. One month before laryngectomy, he had undergone laryngoscopy under general anesthesia and received sugammadex administration without causing hypersensitivity. He had no history of allergies. The operation was finished without complications. Shortly after sugammadex administration, his blood pressure dropped to approximately 70 mmHg, and his heart rate increased to 110 beats/minute with systemic erythema. Suspecting anaphylaxis, he was treated with the intravenous injection of phenylephrine, D-chlorpheniramine, and hydrocortisone. After these treatments, his cardiovascular condition stabilized. Eight months after the event, skin prick tests and intradermal tests with all agents used during general anesthesia were performed. Intradermal tests showed positive results only for sugammadex. Subsequently, basophil activation tests with CD203c were performed using sugammadex, γ-cyclodextrin, and positive controls (anti-immunoglobulin-E and formyl-methionyl-leucyl-phenylalanine). In addition to both controls, sugammadex, but not γ-cyclodextrin, induced significant upregulation of CD203c expression. We performed additional basophil activation tests with wortmannin, an inhibitor of phosphoinositide 3-kinase, to investigate the mechanism underlying sugammadex-induced basophil activation. The inhibitory effect of wortmannin on basophil activation due to sugammadex was similar to that of anti-immunoglobulin-E, suggesting an immunoglobulin-E-dependent mechanism. Although the patient showed no hypersensitivity after the first exposure of sugammadex, anaphylaxis appeared after the second administration. Because most cases of sugammadex-induced anaphylaxis reportedly appeared after first administration, this seems to be a rare case.
    Conclusions: In the present case, sugammadex-induced anaphylaxis might have occurred through an immunoglobulin-E-dependent mechanism and not involve γ-cyclodextrin as an epitope. Physicians should pay attention to the occurrence of sugammadex-induced anaphylaxis even when the patient has a history of safe administration of sugammadex.
    MeSH term(s) Anaphylaxis/chemically induced ; Epitopes ; Humans ; Immunoglobulin E ; Male ; Middle Aged ; Phosphatidylinositol 3-Kinases ; Sugammadex ; gamma-Cyclodextrins/adverse effects
    Chemical Substances Epitopes ; gamma-Cyclodextrins ; Sugammadex (361LPM2T56) ; Immunoglobulin E (37341-29-0)
    Language English
    Publishing date 2021-06-05
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2269805-X
    ISSN 1752-1947 ; 1752-1947
    ISSN (online) 1752-1947
    ISSN 1752-1947
    DOI 10.1186/s13256-021-02894-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma.

    Miyazawa, Yuri / Yokohama, Akihiko / Ishizaki, Takuma / Tsukamoto, Norifumi / Koshi, Hiromi / Hirato, Junko / Handa, Hiroshi

    International journal of hematology

    2021  Volume 113, Issue 4, Page(s) 592–599

    Abstract: Composite lymphoma (CL) is a very rare clinical entity defined by the presence of two or more different subtypes of lymphoma in the same lymph node. We report a case of CL in a 78-year-old male presenting with leukocytosis and swelling of multiple lymph ... ...

    Abstract Composite lymphoma (CL) is a very rare clinical entity defined by the presence of two or more different subtypes of lymphoma in the same lymph node. We report a case of CL in a 78-year-old male presenting with leukocytosis and swelling of multiple lymph nodes. A left axillary node biopsy showed atypical lymphocytes in both the interfollicular and follicular areas. Immunohistochemistry revealed that mantle cell lymphoma (MCL) was mainly present in the interfollicular area and follicular lymphoma (FL) was present in the follicular area. Polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangements confirmed that they were clonally related neoplasms. However, Epstein-Barr virus (EBV) DNA was detected in only FL cells, suggesting that MCL and FL had split into two clones in the early steps of pathogenesis. This is the first reported case of CL with EBV-negative B-cell non-Hodgkin lymphoma (NHL) and EBV-positive B-cell NHL with a clonal relationship. We discuss the developmental processes of these two lymphomas.
    MeSH term(s) Biopsy ; Bone Marrow/pathology ; Composite Lymphoma/diagnosis ; Composite Lymphoma/etiology ; Disease Susceptibility ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Infections/virology ; Herpesvirus 4, Human ; Humans ; Immunohistochemistry ; Immunophenotyping ; In Situ Hybridization, Fluorescence ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/etiology ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/etiology ; Tomography, X-Ray Computed
    Language English
    Publishing date 2021-01-02
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 1076875-0
    ISSN 1865-3774 ; 0917-1258 ; 0925-5710
    ISSN (online) 1865-3774
    ISSN 0917-1258 ; 0925-5710
    DOI 10.1007/s12185-020-03035-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Apheresis on aged patients/donors with complicated backgrounds like ischemic heart disease, arrhythmia, and others.

    Yokohama, Akihiko / Yokote, Keiko / Maruhashi, Takayuki

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2018  Volume 57, Issue 5, Page(s) 619–622

    Abstract: Peripheral blood stem cells (PBSCs) are currently one of the most important stem cell sources for hematopoietic stem cell transplantation as well as cell therapy for ischemic heart disease or critical limb ischemia. Thus, it is sometimes necessary to ... ...

    Abstract Peripheral blood stem cells (PBSCs) are currently one of the most important stem cell sources for hematopoietic stem cell transplantation as well as cell therapy for ischemic heart disease or critical limb ischemia. Thus, it is sometimes necessary to collect autologous PBSCs from donors who have comorbidities. In terms yield, a sufficient number of PBSCs can be collected from donors with comorbidities for performing cell therapy if their age is < 60 years or up to a maximum of 70 years, although the number of PBSCs collected from older donors would probably be lower than that obtained from younger donors. On the other hand, granulocyte colony-stimulating factor (G-CSF) administration sometimes results in severe adverse events (AEs), such as ischemic heart disease and vascular thrombosis. Therefore, it is very important to perform strict medical check-ups according to the standards for donor operations in each country before apheresis. The apheresis procedure and G-CSF administration should be performed after administering the appropriate treatment. There is very less information available regarding AEs related to citrate administration during apheresis in aged donors with complicated medical histories. Medical staff should have knowledge of the electrocardiogram (ECG) QTc prolongation that occurs during apheresis owing to hypocalcemia caused by citrate administration, necessitating electrocardiographic monitoring of patients. Calcium should be administered during apheresis to prevent citrate related symptoms.
    MeSH term(s) Aged ; Arrhythmias, Cardiac/therapy ; Blood Component Removal/methods ; Female ; Humans ; Male ; Myocardial Ischemia/therapy ; Tissue Donors
    Language English
    Publishing date 2018-09-18
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2018.09.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.

    Awata-Shiraiwa, Maaya / Yokohama, Akihiko / Kanai, Yukihiro / Gotoh, Nanami / Kasamatsu, Tetsuhiro / Handa, Hiroshi / Saitoh, Takayuki / Murakami, Hirokazu / Hirato, Junko / Ikota, Hayato / Tsukamoto, Norifumi

    Acta haematologica

    2023  Volume 146, Issue 5, Page(s) 384–390

    Abstract: Introduction: Waldenström macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphoma (LPL) with the immunoglobulin (Ig)M paraprotein. MYD88 L265P and CXCR4 mutations are common mutations in WM patients, and mutations in ARID1A and KMT2D ( ... ...

    Abstract Introduction: Waldenström macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphoma (LPL) with the immunoglobulin (Ig)M paraprotein. MYD88 L265P and CXCR4 mutations are common mutations in WM patients, and mutations in ARID1A and KMT2D (MLL2) have also been reported. However, little information has been accumulated on genetic changes in LPL with other paraproteins like IgG.
    Methods: We therefore aimed to evaluate genetic differences between WM and LPL with non-IgM paraprotein (non-IgM-type LPL) using targeted next-generation sequencing (NGS) in 20 Japanese patients (10 with WM, 10 with non-IgM-type LPL).
    Results: Mutations were detected in ARID1A (10%), CXCR4 (20%), MYD88 (90%), and KMT2D (0%) for WM patients and in ARID1A (10%), CXCR4 (20%), MYD88 (70%), and KMT2D (10%) for non-IgM-type LPL patients. No significant differences were identified. No mutations were detected in NOTCH2, PRDM1, CD274 (PD-L1), PDCD1LG2 (PD-L2), RAG2, MYBBP1A, TP53, or CD79B.
    Discussion: Mutant allele frequency in MYD88 L265P did not differ significantly between WM and non-IgM-type LPL. Most mutations detected by NGS were subclonal following MYD88 L265P, although one non-IgM-type LPL patient harbored only CXCR4 S338X mutation. Our NGS analyses reveal genetic characteristics in LPL patients and suggest genetic similarities between these two subsets of LPL, WM and non-IgM-type.
    MeSH term(s) Humans ; Waldenstrom Macroglobulinemia/genetics ; Waldenstrom Macroglobulinemia/pathology ; Myeloid Differentiation Factor 88/genetics ; Mutation ; Lymphoma, B-Cell ; Paraproteins/genetics ; DNA-Binding Proteins/genetics ; Transcription Factors/genetics ; RNA-Binding Proteins/genetics
    Chemical Substances Myeloid Differentiation Factor 88 ; Paraproteins ; MYBBP1A protein, human ; DNA-Binding Proteins ; Transcription Factors ; RNA-Binding Proteins
    Language English
    Publishing date 2023-03-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000530100
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Sub-lethal doses of chemotherapeutic agents induce senescence in T cells and upregulation of PD-1 expression.

    Kasamatsu, Tetsuhiro / Awata-Shiraiwa, Maaya / Ishihara, Rei / Murakami, Yuki / Masuda, Yuta / Gotoh, Nanami / Oda, Tsukasa / Yokohama, Akihiko / Matsumura, Ikuko / Handa, Hiroshi / Tsukamoto, Norifumi / Murakami, Hirokazu / Saitoh, Takayuki

    Clinical and experimental medicine

    2023  Volume 23, Issue 6, Page(s) 2695–2703

    Abstract: Cellular senescence is a stable cell cycle arrest, usually in response to internal and/or external stress, including telomere dysfunction, abnormal cellular growth, and DNA damage. Several chemotherapeutic drugs, such as melphalan (MEL) and doxorubicin ( ... ...

    Abstract Cellular senescence is a stable cell cycle arrest, usually in response to internal and/or external stress, including telomere dysfunction, abnormal cellular growth, and DNA damage. Several chemotherapeutic drugs, such as melphalan (MEL) and doxorubicin (DXR), induce cellular senescence in cancer cells. However, it is not clear whether these drugs induce senescence in immune cells. We evaluated the induction of cellular senescence in T cells were derived from human peripheral blood mononuclear cells (PBMNCs) in healthy donors using sub-lethal doses of chemotherapeutic agents. The PBMNCs were kept overnight in RPMI 1640 medium with 2% phytohemagglutinin and 10% fetal bovine serum and then cultured in RPMI 1640 with 20 ng/mL IL-2 and sub-lethal doses of chemotherapeutic drugs (2 μM MEL and 50 nM DXR) for 48 h. Sub-lethal doses of chemotherapeutic agents induced phenotypes associated with senescence, such as the formation of γH2AX nuclear foci, cell proliferation arrest, and induction of senescence-associated beta-galactosidase (SA-β-Gal) activity, (control vs. MEL, DXR; median mean fluorescence intensity (MFI) 1883 (1130-2163) vs. 2233 (1385-2254), 2406.5 (1377-3119), respectively) in T cells. IL6 and SPP1 mRNA, which are senescence-associated secretory phenotype (SASP) factors, were significantly upregulated by sublethal doses of MEL and DXR compared to the control (P = 0.043 and 0.018, respectively). Moreover, sub-lethal doses of chemotherapeutic agents significantly enhanced the expression of programmed death 1 (PD-1) on CD3 + CD4 + and CD3 + CD8 + T cells compared to the control (CD4 + T cells; P = 0.043, 0.043, and 0.043, respectively, CD8 + T cells; P = 0.043, 0.043, and 0.043, respectively). Our results suggest that sub-lethal doses of chemotherapeutic agents induce senescence in T cells and tumor immunosuppression by upregulating PD-1 expression on T cells.
    MeSH term(s) Humans ; Programmed Cell Death 1 Receptor/genetics ; Up-Regulation ; Leukocytes, Mononuclear ; Cellular Senescence/genetics ; Doxorubicin/pharmacology ; CD4-Positive T-Lymphocytes
    Chemical Substances Programmed Cell Death 1 Receptor ; Doxorubicin (80168379AG)
    Language English
    Publishing date 2023-03-13
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2053018-3
    ISSN 1591-9528 ; 1591-8890
    ISSN (online) 1591-9528
    ISSN 1591-8890
    DOI 10.1007/s10238-023-01034-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.

    Shimizu, Hiroaki / Yokohama, Akihiko / Ishizaki, Takuma / Hatsumi, Nahoko / Takada, Satoru / Saitoh, Takayuki / Sakura, Toru / Handa, Hiroshi

    Leukemia research

    2021  Volume 103, Page(s) 106535

    Abstract: Additional cytogenetic abnormality (ACA) acquisition at relapse has been recognized as clonal evolution at the cytogenetic level, and has a significant prognostic impact on relapsed acute myeloid leukemia (AML) patients. We retrospectively investigated ... ...

    Abstract Additional cytogenetic abnormality (ACA) acquisition at relapse has been recognized as clonal evolution at the cytogenetic level, and has a significant prognostic impact on relapsed acute myeloid leukemia (AML) patients. We retrospectively investigated 48 relapsed Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) patients to clarify the clinical significance of ACA acquisition at the first relapse. Twenty-seven patients (56 %) acquired ACA at the first relapse. No significant predisposing factor for ACA acquisition was identified. Notably, patients with ACA acquisition showed a significantly lower second complete remission rate compared to those without ACA acquisition (14.8 % vs. 76.2 %, respectively; p < 0.01), and furthermore, the overall survival rates after the first relapse were significantly different between patients with and without ACA acquisition (25.9 % vs. 55.3 % at 1 year, respectively; p < 0.01). Multivariate analysis extracted ACA acquisition as the only negative prognostic factor (hazard ratio: 2.55, p < 0.01). All seven patients with ACA acquisition who underwent allogeneic transplant died within 2 years after relapse. These findings suggested that clonal evolution detected with conventional cytogenetic analysis at the first relapse triggers severe chemo-refractoriness in Ph-negative ALL cells, just like AML cells. Novel therapeutic strategies are warranted for this subset of patients.
    MeSH term(s) Adolescent ; Adult ; Aged ; Allografts ; Chromosome Aberrations ; Cytogenetic Analysis ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Recurrence ; Survival Rate
    Language English
    Publishing date 2021-02-14
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2021.106535
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Human telomerase reverse transcriptase expression in a CD34-positive hematopoietic progenitor of myelodysplastic syndrome and acute myelogenous leukemia.

    Handa, Hiroshi / Nishimoto, Natsumi / Inoue, Madoka / Yokohama, Akihiko / Tsukamoto, Norifumi / Saitoh, Takayuki / Murakami, Hirokazu

    Hematological oncology

    2019  Volume 37, Issue 4, Page(s) 520–522

    MeSH term(s) Antigens, CD34 ; Female ; Gene Expression Regulation, Enzymologic ; Gene Expression Regulation, Leukemic ; Hematopoietic Stem Cells/enzymology ; Hematopoietic Stem Cells/pathology ; Humans ; Leukemia, Myeloid, Acute/enzymology ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Male ; Myelodysplastic Syndromes/enzymology ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/pathology ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Telomerase/biosynthesis ; Telomerase/genetics
    Chemical Substances Antigens, CD34 ; Neoplasm Proteins ; TERT protein, human (EC 2.7.7.49) ; Telomerase (EC 2.7.7.49)
    Language English
    Publishing date 2019-05-30
    Publishing country England
    Document type Letter
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Two cases of follicular lymphoma with MYC gene abnormalities that presented with bone marrow necrosis.

    Miyazawa, Yuri / Takei, Hisashi / Kobayashi, Nobuhiko / Akashi, Naoki / Sairenji, Yukiko / Sugisaki, Manato / Naito, Chiaki / Ishikawa, Tetsuya / Shimizu, Hiroaki / Ishizaki, Takuma / Yokohama, Akihiko / Tsukamoto, Norifumi / Yoshida, Yuka / Matsumura, Nozomi / Takayama, Yoshiyasu / Handa, Hiroshi

    Journal of clinical and experimental hematopathology : JCEH

    2022  Volume 62, Issue 4, Page(s) 208–216

    Abstract: Bone marrow necrosis (BMN) occurs most frequently in hematological malignancies and sometimes in non-hematological disorders. Lymphoid diseases causing necrosis are regarded as high-grade disease. B-lymphoblastic leukemia/lymphoma is the most common ... ...

    Abstract Bone marrow necrosis (BMN) occurs most frequently in hematological malignancies and sometimes in non-hematological disorders. Lymphoid diseases causing necrosis are regarded as high-grade disease. B-lymphoblastic leukemia/lymphoma is the most common malignant cause of BMN. Here, we present two patients with follicular lymphoma (FL) and MYC gene abnormalities who developed BMN. In one case of BMN, the necrosis disappeared in response to chemotherapy, and the patient survived with complete remission. In the other case, BMN remained even after chemotherapy, and effective chemotherapy could not be administered due to suppressed hematopoiesis, which led to the lymphoma worsening and the patient's death. Indolent lymphomas, such as FL, as in these cases, have the potential to develop BMN. It is important to detect the development of BMN and administer chemotherapy early to improve patient prognosis, since severe BMN prevents patients from receiving effective treatment.
    MeSH term(s) Humans ; Genes, myc ; Bone Marrow/pathology ; Lymphoma, Follicular/drug therapy ; Lymphoma, Follicular/genetics ; Lymphoma, Follicular/pathology ; Lymphoma, Non-Hodgkin/pathology ; Necrosis/pathology
    Language English
    Publishing date 2022-10-20
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 2395568-5
    ISSN 1880-9952 ; 1880-9952
    ISSN (online) 1880-9952
    ISSN 1880-9952
    DOI 10.3960/jslrt.22004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Reduction of blood group A antigen on erythrocytes in a patient with myelodysplastic syndrome harboring somatic mutations in RUNX1 and GATA2.

    Hayakawa, Akira / Sano, Rie / Takahashi, Yoichiro / Okawa, Takafumi / Kubo, Rieko / Harada, Megumi / Fukuda, Haruki / Yokohama, Akihiko / Handa, Hiroshi / Kawabata-Iwakawa, Reika / Tsuneyama, Hatsue / Tsukada, Junichi / Kominato, Yoshihiko

    Transfusion

    2021  Volume 62, Issue 2, Page(s) 469–480

    Abstract: Background: Reduction of blood group ABO antigens on red blood cells (RBCs) is well known in patients with leukemias, and this reduction of ABO expression is strongly associated with DNA methylation of the ABO promoter. Previously, we reported a two- ... ...

    Abstract Background: Reduction of blood group ABO antigens on red blood cells (RBCs) is well known in patients with leukemias, and this reduction of ABO expression is strongly associated with DNA methylation of the ABO promoter. Previously, we reported a two-nucleotide deletion in RUNX1 encoding an abnormally elongated protein lacking the trans-activation domain in a patient with myelodysplastic syndrome (MDS) showing A-antigen loss on RBCs. This prompted us to investigate the underlying mechanism responsible for A-antigen reduction on RBCs in another patient with MDS.
    Study design and methods: Screening of somatic mutations was carried out using a targeted sequencing panel with genomic DNA from peripheral blood mononuclear cells from the patient and eleven MDS controls without A- or B-antigen loss. DNA methylation of the ABO promoter was examined by bisulfite genomic sequencing. Transient transfection assays were performed for functional evaluation of mutations.
    Results: Screening of somatic mutations showed missense mutations in RUNX1 and GATA2 in the patient, while no mutation was found in exons of those genes in the controls. There was no significant difference in ABO promoter methylation between the patient and the controls. Transient transfection experiments into COS-7 and K562 cells suggested that the amino acid substitutions encoded by those mutations reduced or lost the trans-activation potential of the ABO expression.
    Conclusion: Considering the discrepancy between the variant frequencies of these mutations and the ratios of the RBCs with A-antigens loss, the antigen reduction might be associated with these somatic mutations and hypermethylation of the ABO promoter.
    MeSH term(s) ABO Blood-Group System/genetics ; Core Binding Factor Alpha 2 Subunit/genetics ; Core Binding Factor Alpha 2 Subunit/metabolism ; Erythrocytes/metabolism ; GATA2 Transcription Factor/genetics ; GATA2 Transcription Factor/metabolism ; Humans ; Leukocytes, Mononuclear ; Mutation ; Myelodysplastic Syndromes/genetics
    Chemical Substances ABO Blood-Group System ; Core Binding Factor Alpha 2 Subunit ; GATA2 Transcription Factor ; GATA2 protein, human ; RUNX1 protein, human
    Language English
    Publishing date 2021-12-16
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.16766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study.

    Orihara, Masaki / Takazawa, Tomonori / Horiuchi, Tatsuo / Sakamoto, Shinya / Nagumo, Kazuhiro / Tomita, Yukinari / Tomioka, Akihiro / Yoshida, Nagahide / Yokohama, Akihiko / Saito, Shigeru

    British journal of anaesthesia

    2019  Volume 124, Issue 2, Page(s) 154–163

    Abstract: Background: Although cases of anaphylaxis caused by sugammadex have been reported, its incidence remains uncertain. Conversely, no studies have evaluated the incidence of anaphylaxis to neostigmine.: Methods: This was a retrospective multicentre ... ...

    Abstract Background: Although cases of anaphylaxis caused by sugammadex have been reported, its incidence remains uncertain. Conversely, no studies have evaluated the incidence of anaphylaxis to neostigmine.
    Methods: This was a retrospective multicentre observational study of patients who underwent surgery under general anaesthesia between 2012 and 2016 to compare the incidence of anaphylaxis with sugammadex with that of neostigmine at four tertiary hospitals in Japan. To ensure the quality of diagnosis, only cases with a clinical history suggestive of anaphylaxis, along with positive results from in vitro or in vivo testing, were assessed.
    Results: From a total of 49 532 patients who received general anaesthesia included in this study, 18 cases of anaphylaxis were reported, of which six were attributable to sugammadex and none to neostigmine. There were no fatalities attributable to anaphylaxis. The incidence of anaphylaxis caused by all drugs or by sugammadex was calculated as 0.036% (95% confidence interval [CI]: 0.022-0.057%) and 0.02% (of the number of sugammadex cases) (95% CI: 0.007-0.044%), respectively.
    Conclusions: The results suggest that neostigmine might be safer than sugammadex when assessing only the incidence of anaphylaxis. We believe that there is room for reconsideration of the choice of reversal agent for neuromuscular blocking agents by all anaesthetists.
    Clinical trial registration: UMIN000022365; UMIN000033561.
    MeSH term(s) Adolescent ; Adult ; Aged ; Anaphylaxis/chemically induced ; Cholinesterase Inhibitors/adverse effects ; Female ; Humans ; Incidence ; Japan ; Male ; Middle Aged ; Neostigmine/adverse effects ; Retrospective Studies ; Sugammadex/adverse effects ; Young Adult
    Chemical Substances Cholinesterase Inhibitors ; Sugammadex (361LPM2T56) ; Neostigmine (3982TWQ96G)
    Language English
    Publishing date 2019-11-30
    Publishing country England
    Document type Comparative Study ; Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 80074-0
    ISSN 1471-6771 ; 0007-0912
    ISSN (online) 1471-6771
    ISSN 0007-0912
    DOI 10.1016/j.bja.2019.10.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top